UA118540C2 - Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю - Google Patents
Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болюInfo
- Publication number
- UA118540C2 UA118540C2 UAA201406826A UAA201406826A UA118540C2 UA 118540 C2 UA118540 C2 UA 118540C2 UA A201406826 A UAA201406826 A UA A201406826A UA A201406826 A UAA201406826 A UA A201406826A UA 118540 C2 UA118540 C2 UA 118540C2
- Authority
- UA
- Ukraine
- Prior art keywords
- chronic pain
- drug delivery
- transmucosal drug
- delivery devices
- pain relief
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Винахід стосується способу лікування хронічного болю у суб'єкта, який цього потребує, де спосіб включає: введення суб'єкту мукоадгезивного пристрою доставки лікарського засобу, де пристрій вводять один або два рази на день, при цьому пристрій має мукоадгезивний шар, який містить від 100 мкг до 0,9 мг бупренорфіну, забуференого до рН між 4,0 та 6,0, та задній шар, забуферений до рН між 4,0 та 4,8; при цьому пристрій забезпечує концентрацію Сmах стаціонарного стану бупренорфіну у плазмі у діапазоні між приблизно 0,156 та приблизно 0,364 нг/мл, так що відбувається лікування суб'єкта від хронічного болю; при цьому суб'єкт являє собою суб'єкта, який раніше приймав опіоїди; і при цьому суб'єкт, якого лікували, відчуває слабкі або помірні звичайні побічні ефекти, характерні для опіоїдів, або не відчуває звичайних побічних ефектів, характерних для опіоїдів.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578755P | 2011-12-21 | 2011-12-21 | |
| PCT/US2012/071330 WO2013096811A2 (en) | 2011-12-21 | 2012-12-21 | Transmucosal drug delivery devices for use in chronic pain relief |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA118540C2 true UA118540C2 (uk) | 2019-02-11 |
Family
ID=48669710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201406826A UA118540C2 (uk) | 2011-12-21 | 2012-12-21 | Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP2793870A4 (uk) |
| JP (1) | JP6255349B2 (uk) |
| KR (4) | KR20210003313A (uk) |
| CN (2) | CN104125828A (uk) |
| AU (4) | AU2012358308A1 (uk) |
| BR (1) | BR112014015329A2 (uk) |
| CA (1) | CA2859859A1 (uk) |
| EA (2) | EA201992762A1 (uk) |
| HK (1) | HK1203365A1 (uk) |
| IL (2) | IL233075A0 (uk) |
| IN (1) | IN2014DN06117A (uk) |
| MX (2) | MX362217B (uk) |
| SG (3) | SG10202012743WA (uk) |
| UA (1) | UA118540C2 (uk) |
| WO (1) | WO2013096811A2 (uk) |
| ZA (1) | ZA201804381B (uk) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021163529A2 (en) * | 2020-02-13 | 2021-08-19 | Biodelivery Sciences International, Inc. | Methods of treatment with buprenorphine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| DE19652188C2 (de) * | 1996-12-16 | 2002-02-14 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| DE19960154A1 (de) * | 1999-12-14 | 2001-07-12 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie |
| OA12215A (en) | 2000-02-08 | 2006-05-09 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations. |
| CA2445346C (en) | 2001-04-27 | 2010-04-06 | Ajinomoto Co., Inc. | N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| DE102005007859A1 (de) * | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen |
| US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| US9522188B2 (en) | 2005-12-13 | 2016-12-20 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
| CA2649107A1 (en) | 2006-04-12 | 2007-10-25 | Spinal Motion, Inc. | Posterior spinal device and method |
| MX2009000745A (es) * | 2006-07-21 | 2009-04-16 | Biodelivery Sciences Int Inc | Dispositivos de suministro transmucosa con admision mejorada. |
| EP1897543A1 (en) * | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| GB0620661D0 (en) * | 2006-10-18 | 2006-11-29 | Pharmasol Ltd | Novel compounds |
| US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
| GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
| CN102056578A (zh) * | 2008-06-23 | 2011-05-11 | 生物递送科学国际公司 | 多向粘膜给药装置及使用方法 |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
-
2012
- 2012-12-21 SG SG10202012743WA patent/SG10202012743WA/en unknown
- 2012-12-21 CA CA2859859A patent/CA2859859A1/en not_active Abandoned
- 2012-12-21 EA EA201992762A patent/EA201992762A1/ru unknown
- 2012-12-21 IN IN6117DEN2014 patent/IN2014DN06117A/en unknown
- 2012-12-21 WO PCT/US2012/071330 patent/WO2013096811A2/en active Application Filing
- 2012-12-21 CN CN201280070389.6A patent/CN104125828A/zh active Pending
- 2012-12-21 MX MX2014007350A patent/MX362217B/es active IP Right Grant
- 2012-12-21 CN CN201910440007.8A patent/CN110123792A/zh active Pending
- 2012-12-21 KR KR1020207038099A patent/KR20210003313A/ko not_active Application Discontinuation
- 2012-12-21 SG SG11201403075XA patent/SG11201403075XA/en unknown
- 2012-12-21 KR KR1020197027379A patent/KR20190110628A/ko active Application Filing
- 2012-12-21 KR KR1020147020237A patent/KR102026321B1/ko active IP Right Grant
- 2012-12-21 KR KR1020227011298A patent/KR20220047889A/ko not_active Application Discontinuation
- 2012-12-21 JP JP2014548962A patent/JP6255349B2/ja active Active
- 2012-12-21 UA UAA201406826A patent/UA118540C2/uk unknown
- 2012-12-21 EA EA201491046A patent/EA034529B1/ru unknown
- 2012-12-21 AU AU2012358308A patent/AU2012358308A1/en not_active Abandoned
- 2012-12-21 EP EP12860757.9A patent/EP2793870A4/en active Pending
- 2012-12-21 BR BR112014015329A patent/BR112014015329A2/pt not_active Application Discontinuation
- 2012-12-21 SG SG10201710667YA patent/SG10201710667YA/en unknown
-
2014
- 2014-06-11 IL IL233075A patent/IL233075A0/en unknown
- 2014-06-18 MX MX2021012154A patent/MX2021012154A/es unknown
-
2015
- 2015-04-22 HK HK15103881.9A patent/HK1203365A1/xx unknown
-
2017
- 2017-11-09 AU AU2017258916A patent/AU2017258916B2/en not_active Ceased
-
2018
- 2018-06-29 ZA ZA2018/04381A patent/ZA201804381B/en unknown
-
2019
- 2019-04-15 AU AU2019202602A patent/AU2019202602A1/en not_active Abandoned
-
2021
- 2021-04-01 AU AU2021202042A patent/AU2021202042A1/en not_active Abandoned
- 2021-07-23 IL IL285091A patent/IL285091A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
| MY163517A (en) | Improved device and method for delivery of a medicament | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| MX340290B (es) | Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación. | |
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| MX2012014521A (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion. | |
| MX365688B (es) | Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino. | |
| MX367070B (es) | Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata. | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| WO2018102261A3 (en) | Boronic derivatives hydroxamates as anticancer agents | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| WO2011100769A3 (en) | Kinase modulators for the treatment of cancer | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| MX2021012154A (es) | Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico. | |
| CL2012000488A1 (es) | Uso de carbon vegetal para tratar una sobredosis de etexilato de dabigatran. | |
| EA201590760A1 (ru) | Применение бремеланотида в терапии женской сексуальной дисфункции | |
| UA86338U (uk) | Спосіб лікування вагітних з гестаційним діабетом | |
| AU2014900743A0 (en) | A method to deliver pain relief with a reduced risk of overdose, using 1:1, 2:1, 3:1 and 4:1 mixtures of naloxone and fentanyl for nasal administration. | |
| NZ724912A (en) | Transmucosal drug delivery devices for use in chronic pain relief | |
| UA69222U (uk) | Спосіб рефлексотерапії хворих з віддаленими наслідками черепно-мозкової травми | |
| UA67427U (uk) | Спосіб лікування фіброзно-кавернозних форм органного туберкульозу | |
| UA45538U (uk) | Спосіб лікування астенічного синдрому у пацієнтів урологічного профілю |